By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has regained compliance with a Nasdaq rule that its stock meet a minimum $1 share price and will remain listed on the exchange, it announced after the close of the market on Thursday.

The company said that it has received notice from Nasdaq that it will continue being listed on the Nasdaq Capital Market under ticker symbol "ROSGD" through Aug. 3, then revert back to ticker symbol "ROSG" on Aug. 4.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.